Abstract
Background Tobacco policies, including clean indoor air laws and cigarette taxes, increase smoking cessation in part by stimulating the use of cessation treatments. We explored whether the mediating effect of such treatments varies across socio-demographic groups.
Methods We used data from 62,165 U.S. adult participants in the 2003 and 2010/11 Current Population Survey-Tobacco Use Supplement (CPS-TUS) who reported smoking cigarettes during the past year. Building on prior structural equation models used to quantify the degree to which smoking cessation treatments (prescription medications, nicotine replacement therapy, counselling/support groups, quitlines, and internet resources) mediated the association between clean indoor air laws, cigarette excise taxes, and recent smoking cessation, we added selected moderators to each model to investigate whether mediation effects varied by sex, race/ethnicity, education, income, and health insurance status.
Results For clean indoor air laws, the mediating effect of prescription medication and nicotine replacement therapies varied significantly between racial/ethnic, age, and education groups in 2003. However, none of these moderation effects remained significant in 2010/11. For cigarette excise taxes in 2010/2011, the mediating effect of counseling was stronger in older adults; whereas, the mediating effect of prescription medications tended to be stronger in younger adults. No other moderator reached statistical significance. Smoking cessation treatments did not mediate the effect of taxes on smoking cessation in 2003 and were not included in these analyses.
Conclusions Sociodemographic differences in how smoking cessation treatment use mediates between clean indoor air laws and smoking cessation have decreased from 2003 to 2010/11. In most cases, policies appear to stimulate smoking cessation treatment use similarly across varied sociodemographic groups.
Competing Interest Statement
Dr. Alexander is past Chair of FDA's Peripheral and Central Nervous System Advisory Committee; has served as a paid advisor to IQVIA; is a Principal and holds equity in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx's National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. All other authors have no disclosures to report.
Funding Statement
This work was supported by the National Institutes of Health (R01DA042738). Ms. Riehm was supported by an NIMH National Research and Service Award (NRSA) (F31MH124330) and by a Doctoral Foreign Study Award from the Canadian Institutes of Health Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses are based on publicly available de-identified data that are exempt from review by the Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: Dr. Alexander is past Chair of FDA’s Peripheral and Central Nervous System Advisory Committee; has served as a paid advisor to IQVIA; is a Principal and holds equity in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. All other authors have no disclosures to report.
Funding: This work was supported by the National Institutes of Health (R01DA042738). Ms. Riehm was supported by an NIMH National Research and Service Award (NRSA) (F31MH124330) and by a Doctoral Foreign Study Award from the Canadian Institutes of Health Research.
Data Availability
CPS-TUS data are available from https://cancercontrol.cancer.gov/brp/tcrb/tus-cps/questionnaires-data.
